ASCO24: Nimbus’ HPK1 inhibitorHPK1 inhibitor shows early promise in renal cell carcinoma

23 May 2024
firstwordpharma.com
Clinical ResultASCOPhase 1
Nimbus Therapeutics shared a snapshot of data from a Phase I/II trial of NDI-101150 that demonstrated the HPK1 inhibitorHPK1 inhibitor led to stable disease or better in six of eight patients with renal cell carcinoma (RCC) who received the oral small molecule. The study results were released ahead of presentation at the American Society of Clinical Oncology (ASCO) annual meeting.
The trial is broadly enrolling patients with advanced solid tumours to receive NDI-101150 monotherapy at doses ranging from 50mg to 200mg, or in combination with Merck’s PD-1 inhibitor Keytruda (pembrolizumab).
Overall, five of 30 evaluable patients (16.7%) who received NDI-101150 showed a clinical benefit. In the dose escalation cohort, one patient with RCC had a complete response, while a second RCC patient exhibited a partial response. Both were pre-treated with multiple lines of therapies, including checkpoint inhibitors.
Additionally, three patients with RCC, pancreatic cancer, and endometrial cancer, respectively, maintained durable stable disease for more than six months while on treatment; the patient with RCC sustained the response for 21 months.
Nimbus said the HPK1 inhibitorHPK1 inhibitor was well tolerated with an acceptable safety profile.
NDI-101150 is Nimbus’ sole clinical programme, after Takeda paid $4 billion upfront in 2022 to snatch up its lead TYK2 inhibitorTYK2 inhibitor.
ASCO Daily Digest – your go-to-source for the key developments emerging from this year's American Society of Clinical Oncology (ASCO) annual meeting. Exclusively for PLUS subscribers – sign up here!
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.